Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression

Several newly developed drugs including JQ1 (BET inhibitor), ABT199 (BCL2 inhibitor), and bortezomib (proteasome inhibitor) may offer novel therapeutic strategies for aggressive diffuse large B-cell lymphoma (DLBCL). We tested these drugs together with doxorubicin in a series of combinations in 16 D...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Wenhan, Clipson, Alexandra, Liu, Hongxiang, Huang, Yuanxue, Dobson, Rachel, Wang, Ming, Johnson, Peter, Du, Ming-Qing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2018
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077152/
https://www.ncbi.nlm.nih.gov/pubmed/30055346
http://dx.doi.org/10.1016/j.tranon.2018.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6077152/
https://www.ncbi.nlm.nih.gov/pubmed/30055346
http://dx.doi.org/10.1016/j.tranon.2018.07.007

Ejemplares similares